Bodies of Ebola victims remain highly infectious and pose a transmission risk
In the forests and fractured communities of the Democratic Republic of Congo, a rare strain of Ebola called Bundibugyo is pressing against the limits of what modern medicine has prepared for — 177 suspected dead, no proven vaccine, and a region where grief and distrust can spread as fast as the virus itself. The World Health Organization, raising its threat assessment to very high on Friday, is not merely cataloguing a disease but confronting the older, harder problem of how science reaches people who have reason not to trust it. Oxford researchers are racing to build a vaccine from borrowed technology, while in a hospital courtyard near Bunia, mourning families set fire to isolation tents — a reminder that containment is as much a human negotiation as a medical one.
- A rare Bundibugyo Ebola strain with no proven vaccine has killed an estimated third of those infected, pushing WHO to its second-highest threat level with 750 suspected cases across DR Congo and spillover into Uganda.
- Violence erupted at Rwampara General Hospital when authorities refused to release an Ebola victim's body — relatives threw projectiles, burned isolation tents, and forced police to fire warning shots as medical workers sheltered under military guard.
- Oxford University is adapting the same platform that built the AstraZeneca Covid vaccine to target Bundibugyo, with clinical trials potentially beginning in two to three months and the Serum Institute of India poised for mass production.
- A second, potentially more powerful experimental vaccine — described as a possible Bundibugyo equivalent of the established Zaire vaccine Ervebo — remains six to nine months from human testing, leaving a dangerous window of vulnerability.
- Rebel-held territories, community mistrust, and active insecurity are blocking health workers from reaching confirmed cases, making trust-building as urgent a priority as the medical response itself.
The World Health Organization raised its Ebola risk assessment for the Democratic Republic of Congo from high to very high on Friday, reflecting the deepening severity of an outbreak driven by the Bundibugyo strain — a rare species of the virus that kills roughly one in three people it infects and for which no proven vaccine exists. Since the outbreak began, 750 suspected cases and 177 suspected deaths have been recorded in DR Congo, with the virus also crossing into Uganda, where two confirmed cases and one death have been linked to travelers from the affected region. WHO chief Dr. Tedros Adhanom Ghebreyesus described the regional risk as high while emphasizing that the global threat remains low — a careful distinction meant to signal urgency without triggering international panic. On Sunday, the organization declared a public health emergency of international concern, stopping short of calling the situation a pandemic.
The absence of established tools against Bundibugyo has sent scientists scrambling. Oxford University is developing a vaccine using the same technological platform behind the AstraZeneca Covid shot, with hopes of entering clinical trials within two to three months. The Serum Institute of India stands ready for mass production once Oxford can supply medical-grade material. A separate experimental vaccine, described by WHO adviser Dr. Vasee Moorthy as the most promising long-term option — potentially the Bundibugyo equivalent of Ervebo, the established vaccine for the more common Zaire strain — is still six to nine months from human testing.
Beyond the laboratory, the outbreak is unfolding in terrain shaped by conflict and broken trust. The vast majority of cases are concentrated in Ituri province, parts of which are controlled by armed groups where health workers face genuine danger. That tension broke into open violence on Sunday at Rwampara General Hospital near Bunia, when staff refused to release the body of a deceased patient — a medically necessary precaution, since Ebola victims remain highly infectious after death. Grieving relatives responded by hurling projectiles at the hospital and setting fire to isolation tents. Police fired warning shots; medical workers were placed under military protection.
The episode crystallized the central dilemma of this response: the same safe-burial protocols that are epidemiologically essential can feel, to families in mourning, like a theft of dignity. In a region where health systems are fragile and rumors travel faster than facts, earning community confidence is not a secondary concern — it is the condition under which everything else becomes possible. Dr. Tedros acknowledged as much on Friday, noting that violence and insecurity are actively impeding containment. The race now runs on two tracks simultaneously: one toward a vaccine, the other toward the harder, slower work of trust.
The World Health Organization escalated its assessment of the Ebola outbreak in the Democratic Republic of Congo on Friday, moving the threat level from high to very high at the national level. The shift reflects the growing severity of a disease outbreak centered on a particularly rare and dangerous strain of the virus, one that has killed an estimated third of those it infects and for which no proven vaccine yet exists.
The Bundibugyo species of Ebola, named for the Ugandan district where it was first identified, has produced 177 suspected deaths and 750 suspected cases across the DR Congo since the outbreak began. Of those, 82 cases have been confirmed with seven confirmed deaths. The virus has also crossed into neighboring Uganda, where two confirmed cases and one death have been recorded—both in people who had traveled from the DR Congo. WHO chief Dr. Tedros Adhanom Ghebreyesus characterized the regional risk as high but stressed that the global threat level remains low, a distinction meant to convey both the seriousness of the immediate situation and the lower likelihood of international spread.
The rarity of Bundibugyo is part of what makes this outbreak particularly challenging. Unlike the more common Zaire strain of Ebola, for which vaccines and treatments have been developed and deployed in previous outbreaks, Bundibugyo has left the global health community with fewer tools. Scientists at Oxford University are now racing to fill that gap. They are developing a new vaccine based on the same technological platform that produced the AstraZeneca Covid vaccine, with hopes of moving into clinical trials within two to three months. The Serum Institute of India has already agreed to handle mass production once Oxford can supply medical-grade material. A separate experimental vaccine is also in development but is expected to take six to nine months before doses are ready for human testing. WHO adviser Dr. Vasee Moorthy called that second vaccine "the most promising" option, suggesting it could eventually function as the Bundibugyo equivalent of Ervebo, the established vaccine for the Zaire species.
Yet vaccine development, however urgent, is only part of the challenge. The outbreak is unfolding in a region fractured by conflict and mistrust. Some cases have been confirmed in rebel-held areas where health workers face security risks and community cooperation is fragile. That fragility erupted into violence on Sunday at Rwampara General Hospital near the city of Bunia in Ituri province, where the vast majority of cases have been concentrated. When hospital staff refused to release the body of a deceased patient—a necessary precaution because bodies of Ebola victims remain highly infectious and pose a transmission risk—angry relatives responded with force. Local politician Luc Malembe Malembe witnessed the scene: crowds threw projectiles at the hospital and set fire to isolation tents. Police fired warning shots to disperse the crowd, and medical workers were placed under military protection as order was restored.
The incident underscores a tension that has defined the response to this outbreak. Safe burial practices are epidemiologically essential—authorities must ensure bodies are handled in ways that prevent viral spread—but those same practices can feel to grieving families like a denial of dignity and closure. Building trust in a war-ravaged region where health systems are already fragile and where rumors about disease spread quickly is proving as critical as the medical response itself. Dr. Tedros emphasized on Friday that trust-building is crucial, acknowledging that violence and insecurity are actively hampering efforts to contain the virus. The WHO declared a public health emergency of international concern on Sunday, though it stopped short of calling the situation a pandemic. The distinction matters: it signals global mobilization without the highest level of alarm. But for the people in the DR Congo and Uganda where the virus is circulating, the distinction is academic. The race is on—for vaccines, for security, for the kind of community confidence that makes containment possible.
Citas Notables
We are now revising our risk assessment to very high at the national level, high at the regional level, and low at the global level.— WHO chief Dr. Tedros Adhanom Ghebreyesus
They started throwing projectiles at the hospital. They even set fire to tents that were being used as isolation wards.— Local politician Luc Malembe Malembe, describing the scene at Rwampara General Hospital
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this is the Bundibugyo strain specifically and not one of the other Ebola types?
Because Bundibugyo is rare. We have vaccines and treatments for Zaire, the most common form. With Bundibugyo, we're essentially starting from scratch. A third of people who get it die, and we have no proven way to stop it yet.
The Oxford vaccine sounds promising, but you said there are no guarantees. What does that actually mean for people right now?
It means the vaccine might not work at all, or it might work partially. They're basing it on their Covid technology, which is smart, but Ebola is a different virus. They need animal testing first, then human trials. That takes time—time the outbreak doesn't have.
What happened at that hospital in Bunia—was that just grief, or is there something deeper about how people there see the health response?
Both. Yes, families are grieving. But in a region torn by war, where trust in institutions is already thin, when authorities say "we can't give you your dead," it can feel like control rather than care. That's the real problem the WHO chief was pointing to.
If the Serum Institute is ready to mass-produce, why does it matter that Oxford needs to supply medical-grade material?
Because you can't just hand over a vaccine design and expect production to start. The material has to meet strict pharmaceutical standards. That's another bottleneck. Even when the vaccine works, getting it made and distributed takes months.
Is there any chance this spreads beyond Africa?
The WHO says the global risk is low right now. But Ebola has crossed borders before. It depends on how quickly they contain it, whether people can travel freely from the region, and whether the virus mutates. The low global risk assessment is based on current conditions, not a guarantee.